CEL-SCI (NYSE:CVM) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of CEL-SCI (NYSE:CVM) in a report released on Friday. The firm issued a sell rating on the stock.

CEL-SCI Trading Down 4.2 %

CVM opened at $0.26 on Friday. The company has a quick ratio of 1.09, a current ratio of 1.07 and a debt-to-equity ratio of 0.66. The firm has a market cap of $20.08 million, a P/E ratio of -0.54 and a beta of 0.67. The business has a fifty day simple moving average of $0.37 and a 200-day simple moving average of $0.65. CEL-SCI has a 52 week low of $0.25 and a 52 week high of $2.39.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of CVM. Thoroughbred Financial Services LLC grew its holdings in CEL-SCI by 40.1% during the fourth quarter. Thoroughbred Financial Services LLC now owns 191,661 shares of the company’s stock valued at $76,000 after purchasing an additional 54,900 shares during the last quarter. Geode Capital Management LLC grew its position in CEL-SCI by 9.6% in the 3rd quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock worth $650,000 after purchasing an additional 53,879 shares during the last quarter. Finally, Plotkin Financial Advisors LLC acquired a new position in CEL-SCI in the 3rd quarter valued at approximately $98,000. 12.08% of the stock is owned by institutional investors and hedge funds.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.